Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xaluritamig + enzalutamide
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Xaluritamig + enzalutamide is an experimental combination of xaluritamig, a novel humanized bispecific T-cell engager antibody, with enzalutamide, an androgen receptor signaling inhibitor, being investigated in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Xaluritamig is designed to bind the tumor-associated antigen STEAP1, expressed in most prostate cancers, and CD3 on T-cells, redirecting T-cells to attack STEAP1-expressing tumor cells. Enzalutamide is a standard androgen receptor inhibitor for prostate cancer that blocks androgen receptor signaling, crucial for prostate cancer cell survival and growth. The combination aims to achieve synergistic efficacy by enhancing immune-mediated tumor cell killing while suppressing androgen receptor-driven cancer cell proliferation. The combination is still under clinical investigation, and its efficacy compared to enzalutamide monotherapy is being studied.
- Other names
- xaluritamig + enzalutamide
02
Targets
CD3 (T-cell surface glycoprotein CD3)STEAP1 (Six-transmembrane epithelial antigen of prostate 1)AR (Adrenergic receptors)
Beyond the preview
Go deeper on xaluritamig + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xaluritamig + enzalutamide.